Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease

Citation for published version:
Kennedy, NA, Jones, G-R, Plevris, N, Patenden, R, Arnott, ID & Lees, CW 2019, 'Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease', Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.02.017

Digital Object Identifier (DOI):
10.1016/j.cgh.2019.02.017

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Clinical Gastroenterology and Hepatology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Title: Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease

Short title: Calprotectin predicts progression in Crohn’s

Authors:

Nicholas A Kennedy: Consultant Gastroenterologist and Honorary Clinical Senior Lecturer at Royal Devon and Exeter NHS Foundation Trust and University of Exeter. At the time of much of this work, NAK was a clinical research fellow at the Western General Hospital, Edinburgh and University of Edinburgh.

Gareth-Rhys Jones: Clinical research fellow at the Western General Hospital, Edinburgh and University of Edinburgh.

Nikolas Plevris: Clinical research fellow at the Western General Hospital, Edinburgh and University of Edinburgh.

Rebecca Patenden: Consultant Biochemist at the Western General Hospital, Edinburgh.

Ian D. Arnott: Consultant Gastroenterologist at the Western General Hospital, Edinburgh.

Charlie W Lees: Consultant Gastroenterologist and Honorary Clinical Senior Lecturer at the Western General Hospital, Edinburgh and University of Edinburgh.

Location where work carried out: Western General Hospital, Edinburgh, UK

Grant support: Dr Nicholas A Kennedy was funded by a Wellcome research training fellowship (grant number 097943)

Abbreviations: FC – fecal calprotectin

Corresponding author: Dr Nicholas A Kennedy, Exeter IBD Group, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW.

Email: n.kennedy@exeter.ac.uk.

Tel: +44 1392 402783

Disclosures: None of relevance to this manuscript.
Writing assistance: None.

Author contributions: The study design was conceived by NAK, CWL and IDA. NAK designed the database used for data collection, and NAK and CWL co-ordinated collection of the data. NAK performed the analysis of the data in discussion with GRJ, NP and CWL. RP provided expertise with respect to the calprotectin assay. NAK, GRJ, NP and CWL drafted the manuscript which was revised in discussion with all authors.

Conflicts of Interest: None of the authors have any conflicts of interest relevant to the published work.

Funding sources: NAK and GRJ were both funded by Wellcome Trust during the course of this study (NAK grant number 097943; GRJ grant number 100469/Z/12/Z)
Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease

Nicholas A Kennedy¹,²,³, Gareth-Rhys Jones²,³, Nikolas Plevris¹,³, Rebecca Patenden⁴, Ian D. Arnott², Charlie W. Lees²,³

¹ IBD Pharmacogenetics, University of Exeter, UK; ² Gastrointestinal Unit, Western General Hospital, Edinburgh, UK; ³ University of Edinburgh, UK ⁴ Department of Clinical Chemistry, Western General Hospital, Edinburgh, UK

Abstract

Background & Aims

Mucosal healing is associated with improved outcomes in patients with Crohn’s disease (CD), but assessment typically requires ileocolonoscopy. Calprotectin can be measured in fecal samples to determine luminal disease activity in place of endoscopy—this measurement is an important component of the treat to target strategy. We investigated whether levels of fecal calprotectin associate with subsequent CD progression.

Methods

We performed a retrospective study of 918 patients with CD (4218 patient-years of follow-up; median, 50.6 months; interquartile range [IQR], 32.8–76.0 months) managed at a tertiary medical center in Edinburgh, United Kingdom, from 2003 through 2015. Patients were included if they had 1 or more fecal calprotectin measurement made 3 months or more following their diagnosis. We collected clinical data and fecal calprotectin measurements and analyzed these data to identify factors associated with a composite outcome of progression in Montreal behavior, hospitalization, and resection.
Results

Increased level of fecal calprotectin at index visit was associated with subsequent progression of CD, independent of symptoms or disease location. The median level of fecal calprotectin at the index visit was 432 µg/g (IQR, 1365–998 µg/g) in patients who reached the composite endpoint vs 180 µg/g (IQR, 50–665 µg/g) in patients who did not. In multivariable analysis, a cutoff of 115 µg/g calprotectin identified patients who met the endpoint with a hazard ratio of 2.4 (95% CI, 1.8–3.1; \( P<.0001 \)).

Conclusion

In a retrospective analysis of patients with CD, we found that measurements of fecal calprotectin made during routine monitoring can identify patients at risk for disease progression, independent of symptoms or disease location. It is therefore important to screen asymptomatic patients for mucosal inflammation and pursue complete resolution of inflammation.

Keywords

IBD; biomarker; prognostic factor; non-invasive
Introduction

Crohn’s disease (CD), a form of inflammatory bowel disease (IBD), is characterized by relapsing episodes of intestinal inflammation and the accumulation of irreversible digestive damage. Prognosis is highly variable between individuals,¹ such that the identification of patients at greatest risk of poor outcomes is an urgent research priority. Some clinical phenotypes, such as disease location and environmental factors such as smoking, have been clearly associated with poorer outcomes.²,³ However, accurate prediction remains difficult. Over the past decade, there has been a paradigm shift away from treating until symptom resolution and towards mucosal healing as persistent subclinical bowel inflammation leads to poorer outcomes.⁴⁻⁸ However this has typically required ileocolonoscopy, which is invasive, expensive and carries risk for patients.⁹

Fecal calprotectin (FC) has become well-established as a biomarker of intestinal inflammation. Calprotectin is a 36.5 kDa protein that constitutes 60% of the contents of granules in neutrophils.¹⁰ Its use as a screening test to distinguish IBD from irritable bowel syndrome is well-supported by multiple studies, with an AUROC of 0.95 in meta-analysis.¹¹ Several groups have demonstrated that FC correlates well with endoscopic measures of disease activity.¹²⁻¹⁶ There has been greater uncertainty of its role in small bowel CD, but more recently FC has been shown to correlate well with both MRI¹⁷ and capsule endoscopy findings.¹⁸,¹⁹

The use of FC as a prognostic marker has been demonstrated in the context of medically- and surgically-induced remission.²⁰⁻²² In both contexts, baseline FC predicts disease flare over a follow-up period of two years, though there is also a rise notable in FC 3-4 months prior to clinical disease flare. The recent CALM study has demonstrated the effectiveness of a treat to target strategy incorporating FC in Crohn’s disease.²³ However, it has still not yet been demonstrated whether elevations in FC, irrespective of clinical symptoms, are associated with disease progression. This information would provide further support to the principle of treating beyond symptoms.
We aimed to use a large, extensively-phenotyped cohort of CD patients followed over time to determine the value of FC to predict progression of disease. We focused on endpoints associated with digestive damage: progression of Montreal behaviour, surgical resection or hospitalization for severe flare.

Methods

This was a retrospective cohort study of CD patients managed at the Western General Hospital, Edinburgh, UK, a teaching hospital that cares for secondary- and tertiary-referred patients with IBD. The primary inclusion criteria were a diagnosis of CD and at least one FC more than three months post-diagnosis. The a priori primary endpoint was a composite of progression in Montreal luminal disease behavior (B1 to B2/B3 or B2 to B3), hospitalization for flare and resectional surgery. These individual components were also defined as separate secondary endpoints. In order to reduce the possibility of merely measuring the FC at the time of the disease flare that caused the endpoint, any events that happened within 90 days after the index FC were regarded as having already happened and were not included in the endpoint analysis.

We obtained FC data from the Edinburgh FC Registry (EFCR), a record of every FC done in Edinburgh since its introduction in 2003. Patients in this initial cohort had their first FC between 2003 and 2014 and were followed up until 2015. Fecal calprotectins were requested as part of routine monitoring and also directed by patients’ symptoms. These data represent a convenience sample, and include all patients tested during that period who met our inclusion criteria.

We matched these data to existing research and clinical databases to identify patients with a known diagnosis of CD. We then interrogated the electronic and paper medical records to obtain information on demographics, symptoms, disease location and behavior over time, hospitalizations, surgical procedures, investigations and drug therapy. Disease location and behavior were classified according to the Montreal classification. Changes in disease behavior were defined as occurring...
when the first investigation that demonstrated the change was performed, for example an MRI scan showing stricturing small bowel disease.

Patients were regarded as symptomatic either by Harvey Bradshaw Index (HBI) > 4 and/or by physician global assessment of active symptomatic luminal disease. Each of the previous medical therapies was categorized as having ever taken versus never, with immunomodulators defined as azathioprine, mercaptopurine and methotrexate. Data were stored in a Microsoft Access 2003 database (Microsoft, Redmond, WA, USA).

FC collection kits were given to patients and samples returned to the hospital biochemistry laboratories either directly or via their GP practice (samples forwarded the same day). Upon arrival at the laboratories samples are stored at -20 °C. FC was measured using a standard enzyme-linked immunosorbent assay (ELISA) technique (Calpro AS, Norway). All assays were performed utilizing the same protocol in the Department of Clinical Biochemistry at the Western General Hospital, Edinburgh. The manufacturer’s reference range for distinguishing inflammatory bowel disease from functional gut disorders is >50 µg/g.

Statistical analysis was done using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). The Mann Whitney U test was performed for continuous non-parametric data, while Fisher’s exact tests were done for categorical data. Survival analysis was performed using Kaplan Meier and Cox proportional hazards models. For the survival models, we have reported the outcome as the proportion with maintained digestive health, i.e. the inverse of our primary endpoint. Patients were excluded from the specific analysis of progression in Montreal behavior if they were already B3 at baseline.

FC was analyzed using log-transformed data and using a predefined threshold of 250 µg/g. The optimum threshold for FC on survival analysis was then explored by examining the p values of the likelihood ratio test and the Akaike Information Criteria for Cox proportional hazard models. Variable
selection for multivariable models was done using a stepwise backwards method based on Akaike
Information Criterion. We performed Cox proportional hazards analyses of the effect of drug therapy
up to 3 months pre or 6 months post fecal calprotectin on the primary outcome; for this analysis,
patients who had disease progression within the first six months or who were censored in that
period were excluded from analysis. The multistate transition data for disease progression in the
overall cohort was done using the empirical transition matrix method.27

The principal analysis was done using the first FC for each patient where there was more than one.
Owing to the retrospective nature of this dataset, these were not taken at uniform intervals.
Exploratory analysis of multiple FCs was performed using the median for each rolling six-month
period centered on each month following diagnosis and stratified by progression in Montreal
behavior. FCs were excluded from this analysis where the patient was symptomatic at the time of
sampling.

This study was conducted as a service evaluation using data collected routinely as part of clinical
care, and therefore following guidance from the UK Health Research Authority did not require
specific ethical approval or consent.

Results

We identified 918 CD patients meeting our inclusion criteria (Figure 1). 61.1% were female, and
median age at the index FC measurement was 40.7 years (interquartile range [IQR] 28.5-54.8) (Table
1). Median follow-up time was 50.6 months (IQR 32.8-76.0), with a total of 4218 patient-years of
follow-up across the cohort. At diagnosis, 81% had an inflammatory (B1) phenotype, 12% stricturing
(B2) and 8% penetrating (B3). By 30 years post-diagnosis, the proportions of B1, B2 and B3 were
estimated as 29%, 36% and 36% respectively (Figure 2). FC was significantly higher in patients with
L3 (median 315 [IQR 90 – 866] μg/g) and L2 disease (median 289 [IQR 69 – 909] μg/g) than in those
with L1 disease (median 180 [IQR 65 – 445 μg/g]; p<0.0001).
Demographic and biomarker data on the cohort stratified by whether the patients reached the composite endpoint or not are shown in table 2. On univariable cox proportional hazards analysis, FC was strongly associated with an elevated risk of reaching the primary endpoint (Table 3), with a hazard ratio (HR) of 1.79 (95% CI 1.50 – 2.14, p = 1.9×10^{-10}) for log_{10}(FC). The only other blood tests nominally associated with FC on univariable analysis were CRP (p=0.016), hemoglobin (p=0.011) and platelets (p=0.003). There were also associations with younger age at diagnosis (p=0.010), female sex (p=0.021), prior immunomodulator use (p=0.012), symptoms at index visit (p=1.2×10^{-7}). Smoking status, previous intestinal resection, previous anti-TNF and time period of FC measurement (pre/post 2008) use were not associated with the primary endpoint, nor was there a significant difference in the time since diagnosis at the index FC.

On multivariable Cox proportional hazards analysis, disease progression was independently associated with elevated FC, female sex, younger age, ileal/ileocolonic disease, previous immunomodulator use and symptoms (Table 3).

A further analysis was performed to explore the effect of changes in treatment before and after measurement of calprotectin (Supplementary Table 1). This was restricted to patients who did not have disease progression and were not censored within the first six months. There were no significant associations with changes in medication in the three months leading up to the measurement of fecal calprotectin. Use of steroids in the six months following calprotectin was significantly associated with disease progression (HR 1.5 [95% CI 1.16 - 2.03], p=0.003). However, this was no longer significant in a multivariable analysis that also included the FC result (Supplementary Table 2).

Above a threshold FC of 250 µg/g, the hazard ratio for reaching the primary endpoint was 1.9 (95% CI 1.5 – 2.3, p = 5.5×10^{-8}, figure 3A). Using analysis of different thresholds of FC (Supplementary Figure 1), the most significant difference in progression to the primary composite endpoint with a
cut-point of 115 µg/g (figure 3B) yielding a hazard ratio on multivariable analysis of 2.4 (95% CI 1.8 – 3.1, \( p = 7.2 \times 10^{-10} \)). Differences in progression were seen in all three principal Montreal locations (L1, L2 and L3; Supplementary Figure 2), in all three secondary endpoints (Supplementary Figure 3) and independent of symptom status at the index visit (Supplementary Figure 4).

Using the Kaplan-Meier estimates, the positive predictive value of an index FC >115 µg/g was 28%, 43%, 52% and 59% at 2, 4, 6 and 8 years respectively. The negative predictive value of an index FC ≤115 µg/g was 88%, 80%, 74% and 65% at 2, 4, 6, and 8 years respectively.

In a sensitivity analysis by quartiles of time from diagnosis to first fecal calprotectin, the association between calprotectin and disease progression was seen for quartiles 2 to 4, but not for the patients in the first quartile; these patients had 3 to 15.5 months between diagnosis and first fecal calprotectin (Supplementary Figure 5).

We performed an exploratory analysis using all of the available CD FC data and excluding FC taken when patients had symptoms. This analysis included 1456 FCs from 396 patients. The rolling median FC can clearly be seen to differ between those 35/396 patients with a subsequent progression in Montreal behavior and those that did not (Supplementary Figure 6).

**Discussion**

This study demonstrates that elevated FC is associated with increased disease progression, both as defined by a composite primary endpoint of advance in Montreal luminal behavior, surgical resection and hospitalization and by each of these endpoints when considered individually.

Mucosal healing is recognized as a target for therapy in Crohn’s disease, with poorer prognosis and a higher risk of surgery associated with increased endoscopic disease activity. There is a strong correlation between FC, endoscopic disease activity and ulcer depth. Our data show more directly that elevated FC can be used as a marker of increased risk of progression.
Although absolute index FC levels were lower in L1 patients, FC better predicted poorer outcomes in patients with L1/L3 rather than L2 disease distribution. Patients with active colonic disease may be more likely to exhibit symptoms, and thus have earlier intervention. In contrast, patients with active ileal disease may tolerate a higher level of subclinical inflammation, resulting in delay of treatment with a greater risk of progression and complications.

Other variables associated with an adverse outcome in our analysis included younger age, which has previously been identified as an adverse prognostic factor\(^1\), and previous immunomodulator use which is likely to be a marker for a more aggressive prior disease course. Symptomatically active disease was associated with an increased rate of disease progression, independently of elevated FC. This validates a treat-to-target approach aiming for a combination of resolution of symptoms as well as mucosal healing, with FC a marker of the latter.

Thresholds for prediction of disease relapse have varied across the literature, influenced by the disease cohort being studied and the assay used. Several studies have identified a cut-off of 250 µg/g as being useful to distinguish active from inactive disease.\(^{20,22,29}\) In the present study, the optimal separation between survival curves for progression of disease was seen using a lower threshold of 115 µg/g, suggesting that lower levels of inflammatory activity may still be associated with an adverse outcome. However, any such threshold needs to be interpreted in the context of the methods of FC extraction and measurement. For example, others have shown significant variability in FC measurement between weight-based and other methods of FC extraction and similarly when comparing ELISA kits from different manufacturers.\(^{30,31}\)

We have shown that elevated FC at any point in disease course beyond the first year correlates with poorer outcome. Previous studies have demonstrated an increase in symptomatic relapse in patients with elevation of FC,\(^{20–22}\) our study further indicates that this is associated with an increase in disease progression. The CALM study has recently demonstrated better outcomes at 52 weeks when
a strategy incorporating symptoms, CRP and FC was compared with clinical disease activity alone. Together, these data now clearly support a treat-to-target strategy combining a patient-reported symptom score with FC as a marker of mucosal inflammation.

Strengths of the present study include the large number of patients and duration of follow-up, with a median follow-up time following index FC of greater than four years. A clinically relevant definition of disease progression was selected \textit{a priori}, and rich phenotype information was available. Restricting measurement of endpoints to at least 90 days after the index FC should reduce bias from measuring disease activity associated with an exacerbation that went on to cause hospital admission or surgical resection. It can also be observed that the survival curves in figures 3–6 continue to separate for many months after the index FC. This suggests that identification of mucosal inflammation at any point in patient follow up, even at relatively modest levels previously considered acceptable (i.e. FC 115-250ug/g), should warrant careful monitoring and low threshold for treatment escalation decisions.

Limitations of this study relate to its retrospective nature. FCs were not collected at fixed intervals, but as determined by the treating clinician. However, routine monitoring of FC including in asymptomatic patients was established quite early on in Edinburgh after the full roll-out of the test in 2005. The study was also performed at a single centre, which may reduce heterogeneity but at the expense of generalizability. Nonetheless, although the Western General Hospital is a referral centre, it also has a large secondary care population from the local catchment. Finally, medication data were completed as accurately as was possible, but it is possible some courses of steroids, particularly those in primary care, may have been missed. This is unlikely to have introduced any systematic bias.

In conclusion, we have shown in this study that elevated fecal calprotectin is associated with an increased risk of disease progression over time in Crohn’s disease. Further studies should continue
to explore the utility of repeated FC measurements, and to assess whether intervention based on FC can alter disease outcome.

Acknowledgements

Data collection for this study was also undertaken by Miriam Guy, Tom Smith, Joash T Loh, David Haunschmidt, Martina Muscat, Federica Fasci Spurio and Hazel E Drummond. Kathleen Kingstone provided expertise on fecal calprotectin. Colin L Noble, Alan G Shand and Jack Satsangi provided access to their Crohn’s disease patients.

Bibliography

1. Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn’s disease over 15 years. Gut 2012;61:1140–5.
2. Lunney PC, Kariyawasam VC, Wang RR, Middleton KL, Huang T, Selinger CP, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 2015;42:61–70.
3. Sands BE, Arsenault JE, Rosen MJ, Alsahl M, Bailen L, Banks P, et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies. Am J Gastroenterol 2003;98:2712–8.
4. Peyrin-Biroulet L, Sandborn W, Reinisch W, Bemelman W, Bryant R V, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015;110:1324–38.
5. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, et al. Review article: moving towards common therapeutic goals in Crohn’s disease and rheumatoid arthritis. Aliment Pharmacol Ther 2017;45:1058–72.
6. Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.
7. Schnitzler F, Fiddler H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15:1295–301.
8. Allez M, Lemann M, Bonnet J, Cattan P, Jain R, Modigliani R. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947–53.
9. Lohsiriwat V. Colonoscopic perforation: incidence, risk factors, management and outcome. World J Gastroenterol 2010;16:425–30.
10. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating
protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.

11. von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.

12. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–24.

13. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851–8.

14. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162–9.

15. Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–6.

16. Sipponen T, Kärkkäinen P, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008;28:1221–9.

17. Pendsé DA, Makanyanga JC, Plumb AA, Bhatnagar G, Atkinson D, Rodriguez-Justo M, et al. Diffusion-weighted imaging for evaluating inflammatory activity in Crohn’s disease: comparison with histopathology, conventional MRI activity scores, and faecal calprotectin. Abdom Radiol (New York) 2017;42:115–23.

18. Bar-Gil Shitrit A, Koslowsky B, Livovsky DM, Shitrit D, Paz K, Adar T, et al. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn’s disease in patients undergoing capsule endoscopy. Scand J Gastroenterol 2016;51:1–6.

19. Kopylov U, Yung DE, Engel T, Avni T, Battat R, Ben-Horin S, et al. Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016;28:1137–44.

20. de Suray N, Salleron J, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. P274 Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn’s disease patients. A sub-analysis of the STORI study. J Crohn’s Colitis 2012;6:S118–9.

21. Zhulina Y, Cao Y, Amcoff K, Carlson M, Tysz C, Halfvarson J. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease. Aliment Pharmacol Ther 2016;44:495–504.

22. Diederen K, Hoekman DR, Leek A, Wolters VM, Hummel TZ, de Meij TG, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther 2017;45:951–60.

23. Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vañásek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet (London, England) 2017; Epub ahead of print Oct 31, 2017. Available from doi:10.1016/S0140-6736(17)32641-7.
24. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5–36.

25. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (London, England) 1980;1:514.

26. Terry M. Therneau, Patricia M. Grambsch. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.

27. Allignol A, Schumacher M, Beyersmann J. Empirical Transition Matrix of Multi-State Models: The {etm} Package. J Stat Softw 2011;38:1–15.

28. Goutorbe F, Goutte M, Minet-Quinard R, Boucher A-L, Pereira B, Bommelaer G, et al. Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn’s Disease. J Crohn’s Colitis 2015;9:1113–9.

29. Dhaliwal a, Zeino Z, Tomkins C, Cheung M, Nwokolo C, Smith S, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol 2015;6:14–9.

30. Labaere D, Smismans A, Van Olmen A, Christiaens P, D’Haens G, Moons V, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United Eur Gastroenterol J 2014;2:30–7.

31. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013;50:53–61.

32. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert FJ, Vanasek T, et al. Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn’s Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. Gastroenterology 2017;152:S155.
Table 1 – Baseline demographics of the cohort (n=918)

| Variable                                      | Median (IQR) / Number (%) |
|-----------------------------------------------|---------------------------|
| **Sex**                                       |                           |
| Female                                        | 561 (61.1%)               |
| **Age at diagnosis/years**                    | 27.4 (20.1 - 42.8)        |
| **Age at calprotectin/years**                 | 40.7 (28.5 - 54.8)        |
| **Months to first calprotectin**               | 75.5 (15.5 - 183.8)       |
| **Year of first calprotectin**                 | 2010 (2008 - 2011)        |
| (Range 2003 – 2014)                           |                           |
| **Smoking at diagnosis**                      |                           |
| Current                                       | 229 (32.5%)               |
| Ex                                            | 101 (14.3%)               |
| Never                                         | 375 (53.2%)               |
| **Montreal location**                         |                           |
| L1±L4                                         | 289 (31.7%)               |
| L2±L4                                         | 328 (36.0%)               |
| L3±L4                                         | 288 (31.6%)               |
| Isolated L4                                   | 6 (0.7%)                  |
| **Montreal behavior at diagnosis**            |                           |
| B1                                            | 741 (80.7%)               |
| B2                                            | 106 (11.5%)               |
| B3                                            | 71 (7.7%)                 |
| **Montreal behavior at index calprotectin**   |                           |
| B1                                            | 564 (61.4%)               |
| B2                                            | 200 (21.8%)               |
| B3                                            | 154 (16.8%)               |
| **New medication in 3 months prior to fecal calprotectin** |   |
| Steroids                                      | 91 (9.91%)                |
| Immunomodulator                               | 58 (6.32%)                |
| Anti-TNF                                      | 16 (1.74%)                |
| Any of these                                  | 146 (15.90%)              |
| **New medication in 6 months following fecal calprotectin** |   |
| Steroids                                      | 170 (18.52%)              |
| Immunomodulator                               | 105 (11.44%)              |
| Anti-TNF                                      | 47 (5.12%)                |
| Any of these                                  | 239 (26.03%)              |
Table 2: Demographics and investigations at index visit stratified by whether individuals reached the composite primary endpoint of progression in Montreal behavior, surgical operation or hospitalization.

| Variable                     | Primary endpoint | P     |
|------------------------------|------------------|-------|
|                              | Not reached      | Reached|
| Sex                          |                  |       |
| M                            | 235 (42.4%)      | 105 (32.5%) | 0.005 |
| F                            | 320 (57.7%)      | 217 (67.4%) |
| Age at diagnosis/years       | 28.2 (20.9 - 45.0) | 24.7 (17.9 - 38.1) | 2.3×10⁻⁴ |
| Age at calprotectin/years    | 41.9 (30.0 - 56.3) | 38.0 (26.7 - 49.8) | 2.7×10⁻⁴ |
| Months to first calprotectin  | 69.3 (13.4 - 183.8) | 85.1 (20.0 - 189.5) | 0.234 |
| Montreal location            |                  |       |
| L1                           | 167 (30.3%)      | 110 (34.5%) | 1.7×10⁻⁴ |
| L2                           | 224 (40.6%)      | 88 (27.6%) |
| L3                           | 159 (28.8%)      | 117 (36.7%) |
| Smoker at visit              |                  |       |
| No                           | 263 (75.1%)      | 142 (68.9%) | 0.115 |
| Yes                          | 87 (24.9%)       | 64 (31.1%) |
| Previous resection           | 231 (41.6%)      | 146 (45.3%) | 0.289 |
| Previous immunomodulator     | 255 (45.9%)      | 166 (51.6%) | 0.123 |
| Previous anti-TNF            | 110 (19.8%)      | 68 (21.1%) | 0.664 |
| Symptomatic at index visit   | 195 (53.4%)      | 162 (78.3%) | 2.4×10⁻⁹ |
| Investigation                | n                |       |
| Fecal calprotectin (ug/g)    | 877              | 180 (50 - 665) | 432 (136 - 998) | 6.9×10⁻¹² |
| CRP (mg/L)                   | 375              | 7 (3 - 19) | 10 (4 - 27) | 0.023 |
| ESR (mm/hr)                  | 202              | 21 (11 - 36) | 26 (14 - 41) | 0.045 |
| Albumin (g/L)                | 350              | 40 (36 - 43) | 38 (32 - 43) | 0.097 |
| Hemoglobin (g/L)             | 500              | 148 (139 - 155) | 145 (133 - 154) | 0.009 |
| (scaled to male range)       |                  |       |
| WCC (×10⁹/L)                 | 507              | 7.5 (5.9 - 9.4) | 7.3 (5.8 - 9.5) | 0.785 |
| Platelets (×10⁹/L)           | 489              | 277 (225 - 342) | 305 (249 - 377) | 4.9×10⁻⁴ |

Values shown are medians (interquartile ranges) and numbers (percentages) as appropriate.

P values calculated using Mann Whitney U and Fisher’s exact tests for continuous and categorical data respectively.
Table 3 Univariable and multivariable analyses using Cox proportional hazards models for time to reaching primary endpoint

| Variable                                      | Univariable                |   | Multivariable               |   |
|-----------------------------------------------|----------------------------|---|----------------------------|---|
|                                               | HR (95% CI) | p     | HR (95% CI) | p     |
| Sex (female)                                  | 1.31 (1.04 - 1.65) | 0.021 | 1.66 (1.23 - 2.24) | 0.001 |
| Age at diagnosis/years                        | 0.99 (0.98 - 1.00) | 0.010 |                     |     |
| Age at calprotectin/years                     | 0.99 (0.98 - 1.00) | 0.001 | 0.99 (0.98 - 1.00) | 0.010 |
| No ileal involvement (Montreal L2)            | 0.66 (0.51 - 0.84) | 7.9×10⁻⁴ | 0.60 (0.44 - 0.82) | 0.001 |
| Previous immunomodulator                      | 1.32 (1.06 - 1.64) | 0.012 | 1.39 (1.04 – 1.84) | 0.024 |
| Previous anti-TNF                             | 1.12 (0.86 - 1.46) | 0.411 |                     |     |
| Symptomatic at index visit                    | 2.45 (1.76 - 3.42) | 1.2×10⁻⁷ | 2.07 (1.46 – 2.93) | 4.1×10⁻⁵ |
| Fecal calprotectin (ug/g)*                    | 1.79 (1.50 - 2.14) | 1.9×10⁻¹⁰ | 1.49 (1.17 – 1.89) | 0.001 |
| CRP (mg/L)*                                   | 1.44 (1.07 - 1.93) | 0.016 |                     |     |
| Hemoglobin (g/L) (scaled to male range)       | 0.99 (0.98 - 1.00) | 0.011 |                     |     |
| Platelets (x10^9/L)                           | 1.00 (1.00 - 1.00) | 0.003 |                     |     |

* Variable log₁₀ transformed prior to use in the model. Hazard ratio is for each 10-fold increase in the variable.

HR: Hazard Ratio; CI: Confidence Interval
Figure legends

Figure 1 – Derivation of the cohort of patients with Crohn’s disease, fecal calprotectin (FC) and follow-up data

Figure 2 – Disease progression over time in the whole cohort as estimated by the empirical transition matrix method

Figure 3 – Kaplan-Meier plot of time to reaching primary endpoint stratified by fecal calprotectin > 250 µg/g (A) and > 115 µg/g (B) at index visit

The outcome of maintained digestive health is defined here as the inverse of the primary study endpoint (a composite of progression in Montreal behavior, hospitalization or surgery)
30,454 patients with ≥1 FC (2003-2015)

1339 with Crohn’s disease

977 fully phenotyped

918 with ≥1 FC ≥3m post diagnosis

877 with ≥12m f-up post FC

771 with UC
343 other diagnoses
28,001 not yet classified

362 insufficient records

59 without FC ≥3m post diagnosis

41 with <12m follow-up
Inflammatory (B1)  
Stricturing (B2)  
Penetrating (B3)  

Proportion of patients (%)  

Time post diagnosis/years  

Number at risk  

918  722  514  361  245  157  101
HR = 2.4 (95% CI 1.8 – 3.1)

\[ p = 7.2 \times 10^{-10} \]

HR = 1.9 (95% CI 1.5 – 2.3)

\[ p = 5.5 \times 10^{-8} \]
What you need to know

Background and Context
Fecal calprotectin is a marker of luminal Crohn’s disease (CD) activity. We investigated whether fecal calprotectin associates with subsequent CD progression.

Findings
We have now shown that an increased fecal calprotectin is associated with a long-term increase in disease progression, including hospitalisation, surgery and advance in Montreal behaviour.

Implications for patient care
It is important to screen asymptomatic patients for mucosal inflammation and pursue complete resolution of inflammation.